Considerations for Selecting Therapy in RRMM

A BLA has been accepted by the FDA for 2 belantamab mafodotin combinations that have shown positive results in patients with multiple myeloma.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

The use of CAR T-cell therapy and other sequencing options were discussed for patients with multiple myeloma.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Survival data from the interim analysis of the phase 3 DREAMM-7 trial will be presented at the 2024 ASH Annual Meeting.

Early results from the iMMagine-1 trial show anito-cel as a promising therapy in relapsed/refractory multiple myeloma.